



## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	426	(544/322).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:09
L2	540	(544/324).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:09
L3	9	cathlin.inv. and biwersi.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L4	58	Dennis.inv. and McNamara.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L5	76	Joseph.inv. and Repine.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L6	32	Peter.inv. and Toogood.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L7	12	Scott.inv. and Vanderwel.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L8	12	Scott.inv. and Vanderwel.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	426	(544/322).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:09
L2	540	(544/324).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:09
L3	9	cathlin.inv. and biwersi.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L4	58	Dennis.inv. and McNamara.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L5	76	Joseph.inv. and Repine.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L6	32	Peter.inv. and Toogood.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L7	12	Scott.inv. and Vanderwel.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10
L8	12	Scott.inv. and Vanderwel.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/01/21 09:10



chain nodes :

7 15 16 17

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14

chain bonds :

4-7 5-17 7-9 13-15 14-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

exact/norm bonds :

4-7 7-9 13-15

exact bonds :

5-17 14-16

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14

isolated ring systems :



containing 1 : 9 :

G1

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS16:CLASS17:CLASS





chain nodes :

7 8 21 28

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 22 23 24 25 26 27

chain bonds :

4-7 7-8 14-21 20-22 26-28

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17 17-18  
18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27

exact/norm bonds :

4-7 7-8 14-21 26-28

exact bonds :

20-22

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20 16-17 17-18  
18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27

isolated ring systems :

containing 1 : 9 : 15 :

G1:[\*1],[\*2]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS8:CLASS9:Atom 10:Atom 11:Atom 12:Atom  
13:Atom

14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:CLAS22:Atom 23:Atom  
24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS

10/759,749 ALW

L4 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1226146 CAPLUS

DN 146:13164

TI Nitrogen-containing heterocyclic compounds as inhibitors of B-Raf kinase

IN Gahman, Timothy C.; Lang, Hengyuan; Davis, Robert L.; Scranton, Shawn A.

PA Kalypsys, Inc., USA

SO PCT Int. Appl., 114pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006124874	A2	20061123	WO 2006-US18885	20060511
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI	US 2005-680288P	P	20050512		
	US 2005-680290P	P	20050512		
	US 2005-680291P	P	20050512		
	US 2005-680292P	P	20050512		
	US 2005-680293P	P	20050512		
	US 2005-680294P	P	20050512		
	US 2005-680327P	P	20050512		
IT	915373-02-3 915373-04-5				
	RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(nitrogen-containing heterocyclic compds. as inhibitors of B-Raf kinase)				
RN	915373-02-3 CAPLUS				
CN	2,4-Pyrimidinediamine, N4-(3,4-dimethylphenyl)-N2-2-pyridinyl- (CA INDEX NAME)				




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 915373-04-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[4-(4-morpholinyl)phenyl]-N2-2-pyridinyl- (CA INDEX NAME)

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/759,749 ALW

L4 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:990201 CAPLUS  
DN 146:7404  
TI Theoretical study on stabilities of multiple hydrogen bonded dimers  
AU Xu, Wei; Li, Xi-Chen; Tan, Hongwei; Chen, Guang-Ju  
CS College of Chemistry, Beijing Normal University, Beijing, 100875, Peop.  
Rep. China  
SO Physical Chemistry Chemical Physics (2006), 8(38), 4427-4433  
CODEN: PPCPFQ; ISSN: 1463-9076  
PB Royal Society of Chemistry  
DT Journal  
LA English  
IT 914772-76-2  
RL: PRP (Properties)  
(theor. study on stabilities of multiple hydrogen bonded dimers)  
RN 914772-76-2 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:293263 CAPLUS

DN 144:350705

TI Substituted pyridine and pyrimidine compounds as pharmaceutical agents, their preparation, pharmaceutical compositions, and use in therapy

IN Andersen, Denise Lyn; Chang, Catherine H.; Falsey, James R.; Frohn, Michael J.; Hong, Fang-Tsao; Liao, Hongyu; Liu, Longbin; Lopez, Patricia; Retz, Daniel Martin; Rishton, Gilbert M.; Rzasa, Robert M.; Siegmund, Aaron; Tadesse, Seifu; Tamayo, Nuria; Tegley, Christopher M.

PA USA

SO U.S. Pat. Appl. Publ., 86 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006069110	A1	20060330	US 2005-237513	20050927
	WO 2006037117	A1	20060406	WO 2005-US35134	20050927
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-613762P P 20040927

OS MARPAT 144:350705



IT 881209-99-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of substituted pyridine and pyrimidine compds. as anti-inflammatory, analgesic, or antidiabetic agents)

RN 881209-99-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[4-(1-cyclohexen-1-yl)-2-pyridinyl]-N4-methyl-N2-(2-phenylethyl)- (9CI) (CA INDEX NAME)



10/759,749 ALW


L4 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:194015 CAPLUS  
DN 144:292768  
TI Preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors  
IN Stadtmueller, Heinz; Engelhardt, Harald; Steegmaier, Martin; Baum, Anke;  
Guertler, Ulrich; Schoop, Andreas; Quant, Jens; Solca, Flavio; Hauptmann,  
Rudolf; Reiser, Ulrich; Zahn, Stephan Karl; Herfurth, Lars  
PA Boehringer Ingelheim International G.m.b.H., Germany  
SO PCT Int. Appl., 272 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006021544	A1	20060302	WO 2005-EP54089	20050818
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2006148800	A1	20060706	US 2005-206703	20050817
PRAI	EP 2004-19775	A	20040820		
OS	MARPAT 144:292768				
IT	878150-13-1P 878150-14-2P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors)				
RN	878150-13-1 CAPLUS				
CN	1-Pyrrolidineacetamide, N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-isoindol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 878150-14-2 CAPLUS  
CN 1-Piperidineacetamide, 4-(dimethylamino)-N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-isoindol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 878155-93-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 2,4-di(aminophenyl)pyrimides as protein PLK1 inhibitors)

RN 878155-93-2 CAPLUS

CN Acetamide, 2-bromo-N-[6-[[4-[[2-(2-fluoroethyl)-2,3-dihydro-1-methyl-3-oxo-1H-indol-4-yl]amino]-5-(trifluoromethyl)-2-pyrimidinyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:961232 CAPLUS  
DN 143:253451  
TI Hair coloring compositions containing phenylenediamine or diaminopyridine  
couplers and diaminopyrazole intermediates  
IN Lim, Mu'lll; Zhang, Guiru; Murphy, Bryan Patrick  
PA USA  
SO U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S. Ser. No. 90,377.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005188480	A1	20050901	US 2005-77744	20050311
	US 2003196280	A1	20031023	US 2002-90377	20020304
	US 6887280	B2	20050503		
	WO 2006099115	A2	20060921	WO 2006-US8559	20060310
	WO 2006099115	A3	20061221		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI	US 2002-90377	A2	20020304		
	US 2005-77744	A	20050311		
OS	MARPAT 143:253451				
IT	863298-72-0				
	RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses) (hair coloring compns. containing phenylenediamine or diaminopyridine couplers and diaminopyrazole intermediates)				
RN	863298-72-0 CAPLUS				
CN	Pyrimidinetetramine, N2-(6-amino-2-pyridinyl)- (9CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 ALW

L4 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:517936 CAPLUS  
DN 143:451473  
TI Two novel copper(II) complexes with a novel ligand 2,4-Di(2-aminopyridine)-  
6-methylpyrimidine  
AU Ma, Hai-rui; Wang, Yao-yu; Liu, Ping; Li, Dong-sheng; Shi, Qi-zhen; Lee,  
Gene-hsiang; Peng, Shie-ming  
CS Department of Chemistry, Northwest University, Xian, 710069, Peop. Rep.  
China  
SO Chemical Research in Chinese Universities (2005), 21(3), 365-367  
CODEN: CRCUED; ISSN: 1005-9040  
PB Higher Education Press  
DT Journal  
LA English  
OS CASREACT 143:451473  
IT 848189-14-0  
RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)  
(crystal structure and reactant for preparation of copper complexes)  
RN 848189-14-0 CAPLUS  
CN 2,4-Pyrimidinediamine, 6-methyl-N,N'-di-2-pyridinyl- (9CI) (CA INDEX  
NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:158646 CAPLUS  
DN 142:254587  
TI Methods for treating or preventing autoimmune diseases with  
2,4-pyrimidinediamine compounds  
IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;  
Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger  
PA Rigel Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 276 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005016893	A2	20050224	WO 2004-US24716	20040730
	WO 2005016893	A3	20050609		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004265288	A1	20050224	AU 2004-265288	20040730
	CA 2533377	A1	20050224	CA 2004-2533377	20040730
	US 2005209224	A1	20050922	US 2004-903870	20040730
	US 7122542	B2	20061017		
	US 2005234049	A1	20051020	US 2004-903263	20040730
	EP 1656372	A2	20060517	EP 2004-786150	20040730
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	BR 2004013018	A	20061003	BR 2004-13018	20040730
	CN 1849318	A	20061018	CN 2004-80022235	20040730
	JP 2007500722	T	20070118	JP 2006-522105	20040730
	NO 2006000992	A	20060228	NO 2006-992	20060228
PRAI	US 2003-491641P	P	20030730		
	US 2003-531598P	P	20031219		
	US 2004-572246P	P	20040518		
	US 2004-572256P	P	20040518		
	WO 2004-US24716	W	20040730		
OS	MARPAT 142:254587				
IT	841294-23-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(pyrimidinediamine compds. for treatment or prevention of autoimmune diseases)				
RN	841294-23-3 CAPLUS				
CN	3-Pyridinecarboxylic acid, 2-[[4-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)				

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/759,749 ALW

L4 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:120923 CAPLUS  
DN 142:219300  
TI 2,4-Pyrimidinediamines for use in the treatment or prevention of  
autoimmune diseases  
IN Rajinder, Singh; Ankush, Argade; Li, Hui; Bhamidipati, Somasekhar;  
Carroll, David; Sylvain, Catherine; Clough, Jeffrey; Keim, Holger  
PA Rigel Pharmaceuticals, Inc., USA  
SO PCT Int. Appl., 169 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005012294	A1	20050210	WO 2004-US24920	20040730
	WO 2005012294	A8	20051229		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2005209224	A1	20050922	US 2004-903870	20040730
	US 7122542	B2	20061017		
	US 2005234049	A1	20051020	US 2004-903263	20040730
PRAI	US 2003-491641P	P	20030730		
	US 2003-531598P	P	20031219		
	US 2004-572246P	P	20040518		
	US 2004-572256P	P	20040518		
OS	MARPAT 142:219300				
IT	841294-23-3P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(pyrimidinediamines for use in the treatment or prevention of autoimmune diseases)				
RN	841294-23-3 CAPLUS				
CN	3-Pyridinecarboxylic acid, 2-[[4-[(3,4-dihydro-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b]-1,4-oxazin-6-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)				




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

10/759,749 ALW

L4 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:61565 CAPLUS  
DN 142:328292  
TI Synthesis, characterization and crystal structures of 2,4-di(2-aminopyridine)-6-methylpyrimidine (dapmp), [Cu(dapmp)Cl<sub>2</sub>] and [Cu(dapmp)(CH<sub>3</sub>COO)<sub>2</sub>]·H<sub>2</sub>O  
AU Ma, Hai-Rui; Wang, Yao-Yu; Liu, Ping; Li, Dong-Sheng; Shi, Qi-Zhen; Lee, Gene-Hsiang; Peng, Shie-Ming  
CS Department of Chemistry, Shaanxi Key Laboratory of Physico-Inorganic Chemistiy, Northwest University, Xian, 710069, Peop. Rep. China  
SO Polyhedron (2005), 24(2), 215-220  
CODEN: PLYHDE; ISSN: 0277-5387  
PB Elsevier B.V.  
DT Journal  
LA English  
OS CASREACT 142:328292  
IT 848189-14-0P  
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation, crystal structure and complexation of bis(pyridinylamino)pyrimidine with copper(II))  
RN 848189-14-0 CAPLUS  
CN 2,4-Pyrimidinediamine, 6-methyl-N,N'-di-2-pyridinyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:633921 CAPLUS  
DN 141:174079  
TI Preparation of 2-aminopyridines as cdk4 inhibitors  
IN Biwersi, Cathlin Marie; Mcnamara, Dennis Joseph; Repine, Joseph Thomas;  
Toogood, Peter Laurence; Vanderwel, Scott Norman; Warmus, Joseph Scott  
PA Warner-Lambert Company Llc, USA  
SO PCT Int. Appl., 89 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065378	A1	20040805	WO 2004-IB91	20040109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	CA 2512646	A1	20040805	CA 2004-2512646	20040109
	EP 1590341	A1	20051102	EP 2004-701058	20040109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004006809	A	20051227	BR 2004-6809	20040109
	JP 2006516561	T	20060706	JP 2006-500296	20040109
	US 2004236084	A1	20041125	US 2004-759749	20040116
PRAI	US 2003-440805P	P	20030117		
	WO 2004-IB91	W	20040109		
OS	MARPAT 141:174079				
IT	733038-85-2P, 4-[6-[[5-Amino-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)				
RN	733038-85-2 CAPLUS				
CN	1-Piperazinecarboxylic acid, 4-[6-[[5-amino-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 733038-77-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid ethyl ester hydrochloride  
733038-80-7P, 4-[6-[[5-Bromo-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester  
733038-83-0P, 4-[6-(5-Acetyl-4-aminopyrimidin-2-ylamino)pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733038-84-1P  
733039-16-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-19-5P,  
5-Bromo-N'-cyclopentyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-29-7P, N'-Cyclopentyl-5-nitro-N-[5-(piperazin-1-


yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-30-0P,  
 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxaldehyde 733039-31-1P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid ethyl ester 733039-32-2P, 4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid methyl ester 733039-33-3P, [4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]methanol 733039-34-4P, 1-[4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-35-5P, 3-[4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]but-2-enoic acid ethyl ester 733039-36-6P, 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-37-7P, 5-Nitro-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-38-8P, 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxaldehyde 733039-39-9P, 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid ethyl ester 733039-40-2P, 4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid methyl ester 733039-41-3P, [4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]methanol 733039-42-4P, 1-[4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-43-5P, 3-[4-Amino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]but-2-enoic acid ethyl ester 733039-44-6P, 4-Cyclopentylamino-2-[5-(pyrrolidin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-45-7P, N-[5-(3-Aminopyrrolidin-1-yl)pyridin-2-yl]-N'-cyclopentyl-5-nitropyrimidine-2,4-diamine 733039-46-8P, 4-Cyclopentylamino-2-[5-(morpholin-4-yl)pyridin-2-ylamino]pyrimidine-5-carboxaldehyde 733039-47-9P, 4-Cyclopentylamino-2-[(3,4,5,6-tetrahydro-2H-[1,3']bipyridinyl-6'-yl)amino]pyrimidine-5-carboxylic acid ethyl ester 733039-48-0P, 4-Cyclopentylamino-6-methyl-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidine-5-carboxylic acid methyl ester 733039-49-1P, [2-[5-[Bis(methoxymethyl)amino]pyridin-2-yl]amino]-4-(cyclopentylamino)pyrimidin-5-yl]methanol 733039-50-4P, 1-[4-Benzylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-51-5P, 4-[4-Cyclopentylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]pent-3-en-2-one 733039-52-6P, 4-Amino-2-(pyridin-2-ylamino)pyrimidine-5-carbonitrile 733039-53-7P, 5-Nitro-N-pyridin-2-ylpyrimidine-2,4-diamine 733039-54-8P, 4-Amino-2-(pyridin-2-ylamino)pyrimidine-5-carboxaldehyde 733039-55-9P, 4-Amino-2-(pyridin-2-ylamino)pyrimidine-5-carboxylic acid ethyl ester 733039-56-0P, 5-Bromo-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-57-1P, [4-Amino-2-[5-(morpholin-4-yl)pyridin-2-ylamino]pyrimidin-5-yl]methanol 733039-58-2P, 1-[4-Amino-2-[5-(morpholin-4-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-59-3P, [[6-(5-Acetyl-4-aminopyrimidin-2-ylamino)pyridin-3-yl]oxy]acetic acid 733039-60-6P, 4-Cyclopentylamino-2-[4-hydroxymethyl-5-(pyrrolidin-1-yl)pyridin-2-ylamino]pyrimidine-5-carbonitrile 733039-61-7P, N-[5-(3-Aminopyrrolidin-1-yl)-6-chloropyridin-2-yl]-N'-cyclopentyl-5-nitropyrimidine-2,4-diamine 733039-62-8P, 2-(5-Bromopyridin-2-ylamino)-4-(cyclopentylamino)pyrimidine-5-carboxaldehyde 733039-64-0P, 4-Cyclopentylamino-2-[4,6-dichloro-5-(piperazin-1-yl)pyridin-2-ylamino]-6-methylpyrimidine-5-carboxylic acid methyl ester 733039-65-1P, 2-[2-[5-[Bis(2-methoxyethyl)amino]pyridin-2-yl]amino]-4-(cyclopentylamino)pyrimidin-5-yl]-2-methylpropan-1-ol 733039-66-2P, 1-[4-Phenylamino-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-5-yl]ethanone 733039-67-3P, 4-[4-(3-Hydroxycyclopentylamino)-2-[5-(piperazin-1-yl)pyridin-2-yl]amino]pyrimidin-5-yl]pent-3-en-2-one 733039-68-4P, 4-[5-Cyano-2-(pyridin-2-ylamino)pyrimidin-4-yl]amino]cyclohexanecarboxylic acid 733039-69-5P,

2-(4-Amino-5-nitropyrimidin-2-ylamino)isonicotinic acid  
 733039-70-8P, 4-Amino-6-methyl-2-(pyridin-2-ylamino)pyrimidine-5-carboxaldehyde 733039-71-9P, 5-Iodo-N-pyridin-2-ylpyrimidine-2,4-diamine 733039-72-0P, N-[5-Bromo-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-4-yl]acrylamide 733039-73-1P, N-[5-(Piperazin-1-yl)pyridin-2-yl]-5-prop-1-ynylpyrimidine-2,4-diamine 733039-74-2P, 5-[2-(4-Fluorophenyl)ethyl]-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-75-3P, [[6-(4-Amino-5-allylpyrimidin-2-ylamino)pyridin-3-yl]oxy]acetic acid 733039-76-4P, 5-Bromo-N'-cyclopentyl-N-[5-(pyrrolidin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-77-5P, N-[5-(3-Aminopyrrolidin-1-yl)-6-chloropyridin-2-yl]-5-bromo-N'-cyclopentylpyrimidine-2,4-diamine 733039-79-7P, 5-Bromo-N'-cyclopentyl-N-[4,6-dichloro-5-(piperazin-1-yl)pyridin-2-yl]-6-methylpyrimidine-2,4-diamine 733039-80-0P, N-[5-[Bis(2-methoxyethyl)amino]pyridin-2-yl]-5-bromo-N'-cyclopentylpyrimidine-2,4-diamine 733039-81-1P, 5-Bromo-N'-phenyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-82-2P, 3-[[5-Bromo-2-[5-(piperazin-1-yl)pyridin-2-ylamino]pyrimidin-4-yl]amino]cyclopentanol 733039-83-3P, N'-Cyclopentyl-5-iodo-N-[5-(pyrrolidin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-84-4P, N-[5-(3-Aminopyrrolidin-1-yl)-6-chloropyridin-2-yl]-N'-cyclopentyl-5-iodopyrimidine-2,4-diamine 733039-85-5P, N'-Cyclopentyl-5-iodo-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine 733039-87-7P, 4-[6-(4-Cyclopentylamino-5-formylpyrimidin-2-ylamino)pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733039-88-8P, 4-[6-[[5-Acetyl-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733039-93-5P, 4-[6-[[4-Cyclopentylamino-5-(1-methyl-3-oxobut-1-enyl)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733040-28-3P, 5-Fluoro-N'-isopropyl-N-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-2,4-diamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)

RN 733038-77-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




Ox HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-80-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[6-[[5-bromo-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-83-0 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[(5-acetyl-4-amino-2-pyrimidinyl)amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733038-84-1 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-nitro-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-16-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-19-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-29-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-nitro-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-30-0 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-31-1 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-32-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)






ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-33-3 CAPLUS


CN 5-Pyrimidinemethanol, 4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-34-4 CAPLUS


CN Ethanone, 1-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-35-5 CAPLUS

CN 2-Butenoic acid, 3-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-36-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-37-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-38-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-39-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-40-2 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-41-3 CAPLUS


CN 5-Pyrimidinemethanol, 4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-  
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-42-4 CAPLUS


CN Ethanone, 1-[4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-  
pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-43-5 CAPLUS

CN 2-Butenoic acid, 3-[4-amino-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-  
pyrimidinyl]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-44-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[5-(1-pyrrolidinyl)-2-  
pyridinyl]amino]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-45-7 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-2-pyridinyl]-N4-cyclopentyl-5-nitro- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-46-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-(cyclopentylamino)-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-47-9 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-(1-piperidinyl)-2-pyridinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-48-0 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-6-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-49-1 CAPLUS


CN 5-Pyrimidinemethanol, 2-[[5-[bis(methoxymethyl)amino]-2-pyridinyl]amino]-4-(cyclopentylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-50-4 CAPLUS


CN Ethanone, 1-[4-[(phenylmethyl)amino]-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-51-5 CAPLUS

CN 3-Penten-2-one, 4-[4-(cyclopentylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-52-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-2-(2-pyridinylamino)- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-53-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-54-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 4-amino-2-(2-pyridinylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-55-9 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-amino-2-(2-pyridinylamino)-, ethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-56-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-57-1 CAPLUS

10/759,749 ALW


CN 5-Pyrimidinemethanol, 4-amino-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]-  
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-58-2 CAPLUS


CN Ethanone, 1-[4-amino-2-[[5-(4-morpholinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-59-3 CAPLUS


CN Acetic acid, [[6-[(5-acetyl-4-amino-2-pyrimidinyl)amino]-3-pyridinyl]oxy]-  
(9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-60-6 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(cyclopentylamino)-2-[[4-(hydroxymethyl)-5-(1-pyrrolidinyl)-2-pyridinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-61-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-N4-cyclopentyl-5-nitro- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-62-8 CAPLUS


CN 5-Pyrimidinecarboxaldehyde, 2-[(5-bromo-2-pyridinyl)amino]-4-(cyclopentylamino)- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-64-0 CAPLUS


CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[4,6-dichloro-5-(1-piperazinyl)-2-pyridinyl]amino]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-65-1 CAPLUS

CN 5-Pyrimidineethanol, 2-[[5-[bis(2-methoxyethyl)amino]-2-pyridinyl]amino]-4-(cyclopentylamino)-β,β-dimethyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-66-2 CAPLUS

CN Ethanone, 1-[4-(phenylamino)-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-67-3 CAPLUS


CN 3-Penten-2-one, 4-[4-[(3-hydroxycyclopentyl)amino]-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-5-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-68-4 CAPLUS


CN Cyclohexanecarboxylic acid, 4-[[5-cyano-2-(2-pyridinylamino)-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-69-5 CAPLUS

CN 4-Pyridinecarboxylic acid, 2-[(4-amino-5-nitro-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-70-8 CAPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-amino-6-methyl-2-(2-pyridinylamino)- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-71-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-iodo-N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-72-0 CAPLUS


CN 2-Propenamide, N-[5-bromo-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-73-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[5-(1-piperazinyl)-2-pyridinyl]-5-(1-propynyl)- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-74-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-[2-(4-fluorophenyl)ethyl]-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-75-3 CAPLUS


CN Acetic acid, [[6-[[4-amino-5-(2-propenyl)-2-pyrimidinyl]amino]-3-pyridinyl]oxy]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-76-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[5-(1-pyrrolidinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-77-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-5-bromo-N4-cyclopentyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-79-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-cyclopentyl-N2-[4,6-dichloro-5-(1-piperazinyl)-2-pyridinyl]-6-methyl- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-80-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-[bis(2-methoxyethyl)amino]-2-pyridinyl]-5-bromo-N4-cyclopentyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-81-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-phenyl-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-82-2 CAPLUS

CN Cyclopentanol, 3-[[5-bromo-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-83-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-iodo-N2-[5-(1-pyrrolidinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-84-4 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[5-(3-amino-1-pyrrolidinyl)-6-chloro-2-pyridinyl]-N4-cyclopentyl-5-iodo- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-85-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-cyclopentyl-5-iodo-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-87-7 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-formyl-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-88-8 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[5-acetyl-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-93-5 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[4-(cyclopentylamino)-5-(1-methyl-3-oxo-1-butenyl)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733040-28-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N4-(1-methylethyl)-N2-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


IT 733039-18-4P, 4-[6-[[5-Cyano-4-(cyclopentylamino)pyrimidin-2-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)

RN 733039-18-4 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[6-[[5-cyano-4-(cyclopentylamino)-2-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




10/759,749 ALW

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

IT 733038-79-4, 2-[[5-(4-tert-Butoxycarbonylpiperazin-1-yl)pyridin-2-yl]amino]-4-(cyclopentylamino)pyrimidine-5-carboxylic acid ethyl ester  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)

RN 733038-79-4 CAPLUS

CN 5-Pyrimidinecarboxylic acid, 4-(cyclopentylamino)-2-[[5-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-2-pyridinyl]amino]-, ethyl ester  
(9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW


L4 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:236703 CAPLUS  
DN 140:423636  
TI Solid-Phase Synthesis of 2,4-Diaminopyrimidines via Lewis Acid-Mediated  
Aromatic Nucleophilic Substitution  
AU Arvanitis, Elena A.; Chadha, Naresh; Pottorf, Richard S.; Player, Mark R.  
CS 3-Dimensional Pharmaceuticals Inc., Cranbury, NJ, 08512, USA  
SO Journal of Combinatorial Chemistry (2004), 6(3), 414-419  
CODEN: JCCHFF; ISSN: 1520-4766  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 140:423636  
IT 691402-43-4P 691402-45-6P 691402-61-6P  
691402-63-8P 691402-79-6P 691402-81-0P  
691402-97-8P 691402-99-0P 691403-15-3P  
691403-17-5P 691403-34-6P 691403-36-8P  
691403-59-5P 691403-62-0P 691403-86-8P  
691403-89-1P 691404-13-4P 691404-16-7P  
691404-39-4P 691404-62-3P 691404-65-6P  
691404-87-2P 691404-89-4P 691405-08-0P  
691405-10-4P 691405-26-2P 691405-28-4P  
691405-45-5P 691405-48-8P 691405-64-8P  
691405-66-0P 691405-82-0P 691405-84-2P  
691406-00-5P 691406-02-7P 691406-08-3P  
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP  
(Preparation)  
(solid-phase combinatorial synthesis of 2,4-diaminopyrimidines via  
Lewis acid-mediated aromatic nucleophilic substitution)  
RN 691402-43-4 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-(phenylmethyl)-,  
bis(trifluoroacetate) (9CI) (CA INDEX NAME)  
CM 1  
CRN 691402-42-3  
CMF C17 H17 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2





10/759,749 ALW


RN 691402-45-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-(phenylmethyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-44-5

CMF C23 H21 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-61-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-[(tetrahydro-2-furanyl)methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-60-5

CMF C15 H19 N5 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1

CMF C2 H F3 O2


$$\begin{array}{c} \text{F} \\ | \\ \text{F}-\text{C}-\text{CO}_2\text{H} \\ | \\ \text{F} \end{array}$$

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-[(tetrahydro-2-furanyl)methyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CRN 691402-62-7  
CMF C21 H23 N5 O2




CRN 76-05-1  
CMF C2 H F3 O2



CN 2,4-Pyrimidinediamine, N4-[(4-methylphenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CRN 691402-78-5  
CMF C18 H19 N5




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 ALW

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-81-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(4-methylphenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-80-9

CMF C24 H23 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691402-97-8 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[3-(1-methylethoxy)propyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-96-7

CMF C16 H23 N5 O

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691402-99-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[3-(1-methylethoxy)propyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691402-98-9

CMF C22 H27 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-15-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(2,4-dichlorophenyl)ethyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

10/759,749 ALW


CRN 691403-14-2  
CMF C18 H17 Cl2 N5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 691403-17-5 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-[2-(2,4-dichlorophenyl)ethyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-16-4  
CMF C24 H21 Cl2 N5 O




10/759,749 ALW

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-34-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(3,4-dimethoxyphenyl)ethyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-33-5

CMF C20 H23 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-36-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[2-(3,4-dimethoxyphenyl)ethyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

10/759,749 ALW


CRN 691403-35-7  
CMF C26 H27 N5 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 691403-59-5 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-[(2-methoxyphenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-58-4  
CMF C18 H19 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2

10/759,749 ALW




RN 691403-62-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(2-methoxyphenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-61-9

CMF C24 H23 N5 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691403-86-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[(4-fluorophenyl)methyl]-N2-(5-methyl-2-pyridinyl)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691403-85-7

CMF C17 H16 F N5




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



CM 2 .


CMF C2 H F3 O2



CN 2,4-Pyrimidinediamine, N4-[(4-fluorophenyl)methyl]-N2-[3-(phenylmethoxy)-2-pyridinyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CMF C23 H20 F N5 O



CM 2


CMF C2 H F3 O2



CN 2,4-Pyrimidinediamine, N2-(5-methyl-2-pyridinyl)-N4-propyl-,  
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CMF C13 H17 N5




10/759,749 ALW

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-16-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-(phenylmethoxy)-2-pyridinyl]-N4-propyl-,  
bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-15-6

CMF C19 H21 N5 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691404-39-4 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-  
[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-38-3

CMF C24 H20 N6 O

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-62-3 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-[[ (tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-61-2

CMF C16 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691404-65-6 CAPLUS


CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-[[ (tetrahydro-2-furanyl)methyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

10/759,749 ALW

CM 1

CRN 691404-64-5

CMF C22 H22 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691404-87-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(4-methylphenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-86-1

CMF C19 H18 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/759,749 ALW




RN 691404-89-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[ (4-methylphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691404-88-3

CMF C25 H22 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-08-0 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-07-9

CMF C17 H22 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 ALW

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-10-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[3-(1-methylethoxy)propyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-09-1

CMF C23 H26 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 691405-26-2 CAPLUS


CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-25-1

CMF C19 H16 Cl2 N6

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-28-4 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[2-(2,4-dichlorophenyl)ethyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-27-3

CMF C25 H20 Cl2 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749 ALW


CRN 76-05-1  
CMF C2 H F3 O2



RN 691405-45-5 CAPLUS  
CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-44-4  
CMF C21 H22 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 691405-48-8 CAPLUS  
CN 5-Pyrimidinecarbonitrile, 4-[[2-(3,4-dimethoxyphenyl)ethyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-47-7  
CMF C27 H26 N6 O3



10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-64-8 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[(2-methoxyphenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-63-7

CMF C19 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749 ALW


CRN 76-05-1  
CMF C2 H F3 O2



RN 691405-66-0 CAPLUS  
CN 5-Pyrimidinecarbonitrile, 4-[[[(2-methoxyphenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691405-65-9  
CMF C25 H22 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 691405-82-0 CAPLUS  
CN 5-Pyrimidinecarbonitrile, 4-[[[(4-fluorophenyl)methyl]amino]-2-[(5-methyl-2-pyridinyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-81-9  
CMF C18 H15 F N6

10/759,749 ALW




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691405-84-2 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[[[4-fluorophenyl)methyl]amino]-2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-83-1

CMF C24 H19 F N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2

10/759,749 ALW




RN 691406-00-5 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691405-99-9

CMF C14 H16 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 691406-02-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 2-[[3-(phenylmethoxy)-2-pyridinyl]amino]-4-(propylamino)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 691406-01-6

CMF C20 H20 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2

10/759,749 ALW


CRN 76-05-1  
CMF C2 H F3 O2



RN 691406-08-3 CAPLUS  
CN 5-Pyrimidinecarbonitrile, 2-[(5-methyl-2-pyridinyl)amino]-4-  
[(phenylmethyl)amino]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 691406-07-2  
CMF C18 H16 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:107925 CAPLUS  
DN 140:303243  
TI Two-photon absorption properties of star-shaped compounds based on  
1,3,5-triazine and 1,3,5-trisubstituted benzene  
AU Zhou, Xin; Ren, Ai-Min; Feng, Ji-Kang; Liu, Xiao-Juan  
CS Institute of Theoretical Chemistry, State Key Laboratory of Theoretical  
and Computational Chemistry, Jilin University, Changchun, 130023, Peop.  
Rep. China  
SO THEOCHEM (2004), 668(2-3), 229-234  
CODEN: THEODJ; ISSN: 0166-1280  
PB Elsevier Science B.V.  
DT Journal  
LA English  
IT 676520-46-0  
RL: PRP (Properties)  
(two-photon absorption properties of star-shaped compds. based on  
1,3,5-triazine and 1,3,5-trisubstituted benzene)  
RN 676520-46-0 CAPLUS  
CN 2,4,6-Pyrimidinetriamine, N,N,N',N',N'',N''-hexa-2-pyridinyl- (9CI) (CA  
INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 ALW

L4 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:356443 CAPLUS

DN 138:368916

TI Preparation of heteroarylamines as glycogen synthase kinase 3beta inhibitors

IN Freyne, Eddy Jean Edgard; Buijnsters, Peter Jacobus Johannes Antonius; Willems, Marc; Embrechts, Werner Constant Johan; Love, Christopher John; Janssen, Paul Adriaan Jan; Lewi, Paulus Joannes; Heeres, Jan; De Jonge, Marc Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Van Aken Koen, Jeanne Alfons; Diels, Gaston Stanislas Marcella

PA Janssen Pharmaceutica N.V., Belg.

SO PCT Int. Appl., 88 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003037891	A1	20030508	WO 2002-EP12077	20021029
	WO 2003037891	A8	20030904		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2463822	A1	20030508	CA 2002-2463822	20021029
	EP 1448556	A1	20040825	EP 2002-790307	20021029
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	BR 2002013792	A	20041207	BR 2002-13792	20021029
	CN 1582285	A	20050216	CN 2002-821900	20021029
	HU 200402106	A2	20050228	HU 2004-2106	20021029
	JP 2005507423	T	20050317	JP 2003-540172	20021029
	NZ 531853	A	20060224	NZ 2002-531853	20021029
	US 2005004125	A1	20050106	US 2004-493452	20040423
	NO 2004001911	A	20040510	NO 2004-1911	20040510
PRAI	EP 2001-204196	A	20011101		
	WO 2002-EP12077	W	20021029		

OS MARPAT 138:368916

IT 521951-07-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heteroarylamine derivs. as glycogen synthase kinase 3β (GSK3β) inhibitors for preventing or treating GSK3β-mediated diseases)

RN 521951-07-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-(5-bromo-2-pyridinyl)-N4-(2,4,6-trimethylphenyl)-(9CI) (CA INDEX NAME)

10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/759,749 ALW

L4 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1956:56933 CAPLUS

DN 50:56933

OREF 50:10729d-i,10730a-h

TI Quaternary salts from 2-chloro-5-nitropyrimidines. I. Preparation and some reactions

AU Spickett, R. G. W.; Timmis, G. M.

CS Roy. Cancer Hosp., London

SO Journal of the Chemical Society (1955) 4354-9

CODEN: JCSOA9; ISSN: 0368-1769


DT Journal

LA Unavailable

IT 733039-53-7P, Pyrimidine, 4-amino-5-nitro-2-(2-pyridylamino)-  
857428-16-1P, Pyrimidine, 4-methyl-2,6-bis(6-methyl-2-  
pyridylamino)-5-nitro- 874494-56-1P, Pyrimidine,  
2,4-bis(6-methyl-2-pyridylamino)-5-nitro-  
RL: PREP (Preparation)  
(preparation of)

RN 733039-53-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-nitro-N2-2-pyridinyl- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 857428-16-1 CAPLUS

CN Pyrimidine, 4-methyl-2,6-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 874494-56-1 CAPLUS

CN Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)


10/759,749 ALW



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


10/759,749 ALW

L4 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1952:48660 CAPLUS  
DN 46:48660  
OREF 46:8121g-i,8122a-c  
TI Quaternary salts from 2-chloro-5-nitropyrimidines, and their reactions  
AU Spickett, R. G. W.; Timmis, G. M.  
CS Roy. Cancer Hosp., London  
SO Chemistry & Industry (London, United Kingdom) (1951) 937-9  
CODEN: CHINAG; ISSN: 0009-3068  
DT Journal  
LA Unavailable  
IT 859208-12-1P, Pyrimidine, 4-anilino-5-nitro-2-(2-pyridylamino)-  
874494-56-1P, Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro-  
RL: PREP (Preparation)  
(preparation of)  
RN 859208-12-1 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 874494-56-1 CAPLUS  
CN Pyrimidine, 2,4-bis(6-methyl-2-pyridylamino)-5-nitro- (5CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


10/759,749 ALW

L4 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1948:32077 CAPLUS  
DN 42:32077  
OREF 42:6830e-i,6831a  
TI Synthetic antimalarials. XXVI. Pyridyl- and pyrimidinylaminopyrimidines  
AU Curd, F. H. S.; Graham, W.; Rose, F. L.  
CS Imp. Chem. Industries Ltd., Blackley, UK  
SO Journal of the Chemical Society (1948) 594-7  
CODEN: JCSOA9; ISSN: 0368-1769  
DT Journal  
LA Unavailable  
IT 856851-88-2P, Pyrimidine, 4-(2-diethylaminoethylamino)-6-methyl-2-(2-pyridylamino)-, dihydrochloride 856855-34-0P, Pyrimidine, 4-methyl-6-p-nitroanilino-2-(2-pyridylamino)-, dihydrochloride 856976-15-3P, Pyrimidine, 4-p-chloroanilino-6-methyl-2-(2-pyridylamino)-, dihydrochloride  
RL: PREP (Preparation)  
(preparation of)  
RN 856851-88-2 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



●2 HCl


ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RN 856855-34-0 CAPLUS  
CN INDEX NAME NOT YET ASSIGNED



●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RN 856976-15-3 CAPLUS  
CN Pyrimidine, 4-p-chloroanilino-6-methyl-2-(2-pyridylamino)-, dihydrochloride (5CI) (CA INDEX NAME)

10/759,749 ALW



●2 HCl

ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	9	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	10	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	11	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	12	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	13	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	14	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	15	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	16	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	17	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	18	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	20	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	21	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	22	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		
NEWS X25	X.25 communication option no longer available		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

10/759,749 2

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:23:55 ON 21 JAN 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:24:04 ON 21 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

DICTIONARY FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107597492.str



```

chain nodes :
7 8 21 28
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 22 23 24 25 26
27
chain bonds :
4-7 7-8 14-21 20-22 26-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20
16-17 17-18 18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27
exact/norm bonds :
4-7 7-8 14-21 26-28
exact bonds :
20-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14 15-16 15-20
16-17 17-18 18-19 19-20 22-23 22-27 23-24 24-25 25-26 26-27
isolated ring systems :
containing 1 : 9 : 15 :

```

G1:[\*1],[\*2]

Match level :

```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS

```



10/759,749 2

L1        STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1                STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -    AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 08:24:26 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED -        203 TO ITERATE

100.0% PROCESSED        203 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:    ONLINE    \*\*COMPLETE\*\*

BATCH    \*\*COMPLETE\*\*

PROJECTED ITERATIONS:        3206 TO        4914


PROJECTED ANSWERS:            2442 TO        3958

L2                50 SEA SSS SAM L1

=> d scan

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H18 N6 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):49

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H17 N7 O S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C15 H18 Br N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H12 Cl F3 N6 O4



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C21 H16 N8 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C15 H10 Cl2 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C17 H17 Cl N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H17 N7 S



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C15 H15 N7 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C13 H15 Br N6 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN 4,6-Pyrimidinediamine, 5-nitro-N-(phenylmethyl)-N-2-pyridinyl-N'-[4-(trifluoromethyl)phenyl]- (9CI)  
MF C23 H17 F3 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H13 Br N6 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C15 H11 Cl N8 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C17 H9 Cl F6 N6 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H20 N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H22 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C13 H17 Cl N6




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4,6-Pyrimidinediamine, N'-(3,4-difluorophenyl)-5-nitro-N-(phenylmethyl)-N-  
2-pyridinyl- (9CI)


MF C22 H16 F2 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H12 Br N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C15 H9 Cl2 F N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H14 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C13 H18 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C19 H16 Cl F3 N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C11 H14 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C22 H15 Cl F3 N7 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H11 Br F N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H18 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C17 H15 N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C22 H18 Br F N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C14 H20 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H24 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE




10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4,6-Pyrimidinediamine, N'-(2-methoxyphenyl)-5-nitro-N-(phenylmethyl)-N-2-  
pyridinyl- (9CI)


MF C23 H20 N6 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H11 Br N8 O5



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE.

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C24 H24 N6 O2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H12 F N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H11 Br Cl F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H20 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C13 H18 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C13 H12 Cl N7 O




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H11 Br Cl N7 O3



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C16 H12 Cl2 N6 O2



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H20 N6 O



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C19 H17 N7



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C23 H22 N6 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C19 H17 N7



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C17 H17 Br N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C15 H9 Br2 F N6 O2




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE



10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C18 H15 Cl N6 O4



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

10/759,749 2


L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C22 H18 Cl2 N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10/759,749 2

L2 50 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
IN INDEX NAME NOT YET ASSIGNED  
MF C17 H13 Cl2 F3 N6



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

ALL ANSWERS HAVE BEEN SCANNED

10/759,749 2

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.90

1.11

STN INTERNATIONAL LOGOFF AT 08:25:05 ON 21 JAN 2007

10/759,749 3

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	9	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	10	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	11	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	12	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	13	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	14	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	15	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	16	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	17	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	18	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	19	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	20	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	21	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	22	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS EXPRESS	NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		
NEWS X25	X.25 communication option no longer available		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

10/759,749 3

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:39:48 ON 21 JAN 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:39:55 ON 21 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

DICTIONARY FILE UPDATES: 19 JAN 2007 HIGHEST RN 917943-10-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\107597493.str



chain nodes :

7 15 16 17

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14

chain bonds :

4-7 5-17 7-9 13-15 14-16

ring bonds :

10/759,749 3

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14  
exact/norm bonds :  
4-7 7-9 13-15  
exact bonds :  
5-17 14-16  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-14 10-11 11-12 12-13 13-14  
isolated ring systems :  
containing 1 : 9 :

G1

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 08:40:14 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 204 TO ITERATE

100.0% PROCESSED 204 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 3224 TO 4936

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

10/759,749 3

=> s l1 sss ful

FULL SEARCH INITIATED 08:40:30 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 4123 TO ITERATE

100.0% PROCESSED 4123 ITERATIONS

11 ANSWERS

SEARCH TIME: 00.00.01

L3 11 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 08:40:37 ON 21 JAN 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Jan 2007 VOL 146 ISS 5

FILE LAST UPDATED: 19 Jan 2007 (20070119/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 6 L3

=> d l4 1-6 bib hitstr



L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:916886 CAPLUS

DN 145:314980

TI Preparation of aminopyridine compounds with spleen tyrosine kinase (Syk)-inhibitory activity

IN Kodama, Yoshitoshi; Noji, Satoru; Imamura, Katsuaki; Mizojiri, Ryo; Aoki, Kenta; Takagi, Hideo; Naka, Yuichi; Ito, Goro; Shinoda, Kiyotaka; Fujiwara, Akihito; Kurihara, Kazunori; Tanaka, Masaru

PA Japan Tobacco Inc., Japan

SO PCT Int. Appl., 467pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006093247	A1	20060908	WO 2006-JP304034	20060224
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006205731	A1	20060914	US 2006-363563	20060228
PRAI	JP 2005-52469	A	20050228		
	US 2005-658885P	P	20050304		
	JP 2006-11751	A	20060119		
	US 2006-763045P	P	20060127		

OS MARPAT 145:314980


IT 909290-81-9P 909290-86-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aminopyridine compds. as spleen tyrosine kinase (Syk) inhibitors for treatment and/or prevention of allergic diseases)

RN 909290-81-9 CAPLUS

CN Ethanone, 1-[5-[6-[[6-(dimethylamino)-4-pyrimidinyl]amino]-2-pyridinyl]-2-thienyl]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 909290-86-4 CAPLUS

10/759,749 3

CN    Ethanone, 1-[5-[6-[[6-(dimethylamino)-4-pyrimidinyl]amino]-2-pyridinyl]-2-thienyl]-, O-methyloxime (9CI)    (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 26    THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2005:1329661 CAPLUS

DN 144:69843

TI Preparation of pyrimidine derivatives and analogues as modulators of metabolism for the prophylaxis and treatment of metabolic-related disorders

IN Jones, Robert M.; Semple, Graeme; Xiong, Yifeng; Shin, Young-Jun; Ren, Albert S.; Lehmann, Juerg; Fioravanti, Beatriz; Bruce, Marc A.; Choi, Jin Sun Karoline

PA Arena Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 213 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005121121	A2	20051222	WO 2005-US19318	20050602
	WO 2005121121	A3	20060316		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-577354P P 20040604


IT 871679-03-7P, 6-[[[6-[[[1-(tert-Butoxycarbonyl)piperidin-4-yl]methyl](methyl)amino]pyrimidin-4-yl]amino]nicotinic acid  
 871679-05-9P, 4-[[[6-[(5-Fluoropyridin-2-yl)amino]pyrimidin-4-yl](methyl)amino]methyl]piperidine-1-carboxylic acid tert-butyl ester  
 871679-10-6P, 4-[[Methyl[6-[(5-trifluoromethylpyridin-2-yl)amino]pyrimidin-4-yl]amino]methyl]piperidine-1-carboxylic acid tert-butyl ester

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. and analogs as modulators of metabolism for the prophylaxis and treatment of metabolic-related disorders)

RN 871679-03-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 6-[[[6-[[[1-[(1,1-dimethylethoxy)carbonyl]-4-piperidinyl]methyl]methylamino]-4-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 871679-05-9 CAPLUS

10/759,749 3


CN 1-Piperidinecarboxylic acid, 4-[[[6-[(5-fluoro-2-pyridinyl)amino]-4-pyrimidinyl]methylamino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 871679-10-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[methyl[6-[[5-(trifluoromethyl)-2-pyridinyl]amino]-4-pyrimidinyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2004:633921 CAPLUS  
 DN 141:174079  
 TI Preparation of 2-aminopyridines as cdk4 inhibitors  
 IN Biwersi, Cathlin Marie; Mcnamara, Dennis Joseph; Repine, Joseph Thomas;  
 Toogood, Peter Laurence; Vanderwel, Scott Norman; Warmus, Joseph Scott  
 PA Warner-Lambert Company Llc, USA  
 SO PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004065378	A1	20040805	WO 2004-IB91	20040109
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
	CA 2512646	A1	20040805	CA 2004-2512646	20040109
	EP 1590341	A1	20051102	EP 2004-701058	20040109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2004006809	A	20051227	BR 2004-6809	20040109
	JP 2006516561	T	20060706	JP 2006-500296	20040109
	US 2004236084	A1	20041125	US 2004-759749	20040116
PRAI	US 2003-440805P	P	20030117		
	WO 2004-IB91	W	20040109		
OS	MARPAT 141:174079				
IT	733039-89-9P, N-Cyclopentyl-N'-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-4,6-diamine 733039-90-2P, N-Isopropyl-N'-[5-(piperazin-1-yl)pyridin-2-yl]pyrimidine-4,6-diamine 733039-91-3P, 4-[6-[[6-(Cyclopentylamino)pyrimidin-4-yl]amino]pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 733039-92-4P, N-[5-(3-Aminopyrrolidin-1-yl)pyridin-2-yl]-N'-cyclopentylpyrimidine-4,6-diamine				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(cdk4 inhibitor; preparation of 2-aminopyridines as cdk4 inhibitors for treating cell proliferative disorders)				
RN	733039-89-9 CAPLUS				
CN	4,6-Pyrimidinediamine, N-cyclopentyl-N'-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)				



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-90-2 CAPLUS


CN 4,6-Pyrimidinediamine, N-(1-methylethyl)-N'-[5-(1-piperazinyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-91-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[6-[[6-(cyclopentylamino)-4-pyrimidinyl]amino]-3-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 733039-92-4 CAPLUS

CN 4,6-Pyrimidinediamine, N-[5-(3-amino-1-pyrrolidinyl)-2-pyridinyl]-N'-cyclopentyl- (9CI) (CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 3


L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:107925 CAPLUS  
DN 140:303243  
TI Two-photon absorption properties of star-shaped compounds based on  
1,3,5-triazine and 1,3,5-trisubstituted benzene  
AU Zhou, Xin; Ren, Ai-Min; Feng, Ji-Kang; Liu, Xiao-Juan  
CS Institute of Theoretical Chemistry, State Key Laboratory of Theoretical  
and Computational Chemistry, Jilin University, Changchun, 130023, Peop.  
Rep. China  
SO THEOCHEM (2004), 668(2-3), 229-234  
CODEN: THEODJ; ISSN: 0166-1280  
PB Elsevier Science B.V.  
DT Journal  
LA English  
IT 676520-46-0  
RL: PRP (Properties)  
(two-photon absorption properties of star-shaped compds. based on  
1,3,5-triazine and 1,3,5-trisubstituted benzene)  
RN 676520-46-0 CAPLUS  
CN 2,4,6-Pyrimidinetriamine, N,N,N',N',N'',N''-hexa-2-pyridinyl- (9CI) (CA  
INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 3

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2001:43711 CAPLUS  
DN 134:246534  
TI S- and NH- bridging pyridine- and pyrimidine-based ligands for 2 +  
2, 3 + 3 and 4 + 4 molecular grids: evidence of [2 +  
2]Zn(II) grids  
AU Tuntulani, Thawatchai; Tumcharern, Gamolwan; Volkmer, Dirk  
CS Department of Chemistry, Faculty of Science, Chulalongkorn University,  
Bangkok, 10330, Thailand  
SO Bulletin of the Korean Chemical Society (2000), 21(12), 1245-1248  
CODEN: BKCSDE; ISSN: 0253-2964  
PB Korean Chemical Society  
DT Journal  
LA English  
OS CASREACT 134:246534  
IT 202583-29-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and complexation with zinc)  
RN 202583-29-7 CAPLUS  
CN 4,6-Pyrimidinediamine, N,N'-bis(4,6-dimethyl-2-pyridinyl)-2-methyl- (9CI)  
(CA INDEX NAME)




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



10/759,749 3

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1998:104202 CAPLUS  
DN 128:162178  
TI Novel N-donor heterocyclic ligands and their coordination chemistry  
towards a Cu(II) salt  
AU Tuntulani, Thawatchai; Volkmer, Dirk; Fenske, Dieter; Lehn, Jean-Marie  
CS Department of Chemistry, Faculty of Science, Chulalongkorn University,  
Bangkok, 10330, Thailand  
SO Journal of the Science Society of Thailand (1997), 23(3), 185-198  
CODEN: VKSTDB; ISSN: 0303-8122  
PB Science Society of Thailand  
DT Journal  
LA English  
IT 202583-29-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and complexation with copper)  
RN 202583-29-7 CAPLUS  
CN 4,6-Pyrimidinediamine, N,N'-bis(4,6-dimethyl-2-pyridinyl)-2-methyl- (9CI)  
(CA INDEX NAME)



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE  
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/759,749 3

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

22.19

194.50

STN INTERNATIONAL LOGOFF AT 08:40:54 ON 21 JAN 2007